“We’ve hit the wall in terms of how much more we can leverage an antibody,” says David Apelian, MD, PhD. As the CEO of BlueSphere Bio, Apelian is more than willing to consider alternatives to antibodies. Indeed, BlueSphere is interested in developing therapies that rely on T-cell receptors (TCRs). The company is already using TCR technology to seize opportunities presented by blood-based and solid tumors.

Araris Biotech AG secured $24 million in financing to advance the development of its proprietary antibody-drug conjugate-linker technology and drive its own ADC candidates into the clinic.

IMV is evaluating DPX-based assets in several clinical trials in difficult-to-treat cancer indications, including diffuse large B-cell lymphoma (DLBCL), ovarian, breast, and bladder cancer. Previous studies have shown encouraging results, notably in pa­tients who have failed on prior lines of therapy. MVP-S is the clinical validation and proof of concept of the DPX platform’s potential in hematologic and solid cancer indications with and without CPIs.

“Continued innovation in both conventional and next-generation protein therapeutics, cell and gene therapies, RNA- and DNA-based treatments, and vaccine technologies is driving demand for fill/finish capacity,” says Ping-Yang Yeh, president of AltruBio Taiwan, a subsidiary of AltruBio, Inc.

Mattes says there isn’t an official founding date for TFF Pharmaceuticals (NASDAQ TFFP) as the company sprung from another Austin-based organization known as Lung Therapeutics circa 2017.

A unique approach to pediatric glioma treatment comes from EMulate Therapeutics, a clinical-stage therapeutic device company. EMulate’s proprietary platform uses ultra-low radio frequency energy (ulRFE®) to record and replay a molecule’s digital fingerprint.

The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a bit of a misnomer. Although Earth abounds with pathogens that can maim, kill, paralyze, and poison, the specimens inside this machine — being pipetted left and right behind glass for sequencing — are probably the most innocuous human viruses you will ever encounter.

In another advance, IMV Inc. recently announced positive data in metastatic bladder cancer patients using its cancer vaccine, Maveropepimut-S (MVP-S) – also known as DPX-Survivac.